Luisa F. Escobar-Hoyos, PhD, CRI CLIP Investigator Yale University Area of Research: All Cancers, Pancreatic Cancer Dr. Escobar-Hoyos presents a groundbreaking approach to cancer treatment using an innovative RNA delivery system featuring the RNA-binding antibody TMAB3. This unique antibody efficiently attaches to RNA and exhibits the remarkable ability to reach tumors and deliver RNA payloads to cancer cells within 24 hours, distinguishing it from conventional treatments. TMAB3’s capacity to penetrate cells and specifically target tumor cells ensures precise delivery of RNA to the intended cellular locations. Notably, TMAB3’s strong affinity for various RNA types suggests its potential as a versatile platform for RNA therapy. The aim here is to leverage TMAB3 to deliver a specific RNA that induces an immune response against pancreatic cancer in mouse models, mirroring human disease. This approach provides valuable insights into the dynamic influence of the immune system over time, enhancing the clinical relevance of her findings. If successful in pancreatic cancer models, this RNA therapy could revolutionize the treatment of traditionally resistant tumors, particularly for patients confronting historically challenging cancers. Dr. Escobar-Hoyos’ study challenges the prevailing notion of a pro-tumoral immune response in pancreatic cancer, paving the way for novel treatment possibilities. This pioneering research signifies a potential paradigm shift in RNA-based approaches, offering hope to patients with cancers previously deemed challenging to treat. Projects and Grants Antibody-based delivery of immunogenic RNAs for cold tumors Yale University | Pancreatic Cancer | 2024
